Assessment of the visual pathways in patients with neurofibromatosis-1 by 3d-space technique at 3-tesla

ABSTRACT

Background/aim: We aimed to evaluate the size/tortuosity of the optic nerve (ON), and the dilatation of the ON sheath (ONS) in NF-1 patients with 3T-MRI; and to assess the usefulness of 3D-SPACE in imaging the optic pathway, ON, and ONS in NF-1 patients.

Materials and Methods: Twenty consecutive NF-1 patients without the optic pathway glioma (OPG) (group 1), 16 consecutive NF-1 patients with OPG (group 2), and 19 controls were included in this study. The thickness and tortuosity of the ON and the diameter of the ONS were measured on STIR and 3D-SPACE images.

Results: The thickness of the ON was similar in all groups on STIR images (p>0.05). The mean ONS diameter was higher in group 2 with this sequence (p=0.009). Controls had significantly lower grades of ON tortuosity than groups 1 and 2 (p=0.001), and group 1 had significantly lower ON tortuosity compared to group 2 (p=0.001). Severe tortuosity was only detected in group 2.

Conclusions: ON tortuosity and ONS diameter were increased in NF-1 patients in the presence of OPG. High-resolution cranium imaging with the 3D-SPACE technique at 3T seems to be very helpful for detection of the optic pathway morphology and pathologies in NF-1 patients.

Keywords: Neurofibromatosis type 1, Optic pathway glioma, 3D-SPACE, Optic nerve thickness, Optic nerve sheath diameter, Optic nerve tortuosity.
INTRODUCTION

Neurofibromatosis type 1 (NF-1) is an autosomal dominant neurocutaneous disorder characterized by multiple neurofibromas, cutaneous pigmentation, and skeletal dysplasia [1]. Individuals with NF-1 typically present in childhood with café-au-lait spots, inguinal and axillary freckling and Lisch nodules on the iris [2]. Numerous central nervous system (CNS) manifestations have been identified in NF-1 including optic pathway gliomas (OPGs), optic nerve tortuosity, cerebral astrocytomas, hydrocephalus, and neurofibromatosis bright objects (NBO) on imaging [3].

OPGs are the most common CNS neoplasm in NF-1, encountered in 15% of NF-1 patients [1, 4]. They generally involve the anterior visual pathway. Although 45% are intra-orbital, they can arise from anywhere else in the visual pathway including the optic chiasm, optic tracts, and optic radiations [1]. The last location is relatively rare but exhibits more aggressive behavior [4-8].

Magnetic resonance imaging (MRI) is the method of choice for detection and evaluation of the OPGs and other intracranial manifestations of NF-1 because of its higher soft-tissue contrast resolution and radiation-free multiplanar imaging capability [9]. Many institutions perform screening MRI of the brain with thin slices through the optic nerves and chiasm in all young patients with NF-1, and some authors argued that only do MRI when a reliable eye exam cannot be obtained or there are other clinical abnormalities [1, 6-8]. As a result, many patients with NF-1 undergo MRI during their childhood. In certain cases, multiple MRIs including brain, orbital and/or phase-contrast cine are performed for accurate demonstration of the CNS lesion [8]. Multiple imaging examinations have their own disadvantages such as lower patient cooperation and
comfort, higher specific absorption rate (SAR) level, and increased imaging time/cost [10]. New achievements in MRI technology allow the entire cranium to be scanned three-dimensionally (3D) in thin sections within 5 minutes by 3D sampling perfection and application-optimized contrasts using different flip-angle evolutions (3D-SPACE) technique [11]. The 3D-SPACE technique has the capacity to determine all CNS manifestations of NF-1 patients and to give additional information undetectable with routine MRI sequences in clinical settings.

Optic nerve (ON) tortuosity and ON sheath (ONS) dilatation are the abnormalities of patients with NF-1 [8]. They generally are identified incidentally. Their significance in the prognosis of NF-1 patients has not known in the current clinical practice yet. The incidence of ON tortuosity in patients with NF-1 was presented between 12-31% in previous studies [8, 12].

The present study we evaluated the optic pathways of NF-1 patients with and without OPG with 3 tesla (T) MRI unit. In this study we had two aims: first, to assess the relationship between the presence of OPG and the thickness/tortuosity of the ON and the diameter of the ONS; and second, to investigate the significance of 3D-SPACE sequence in the assessment of the optic pathway of NF-1 patients using at 3T MRI unit. To our knowledge, this is the first study evaluating the optic pathway with the 3D-SPACE sequence in NF-1 patients at 3T.

MATERIALS and METHODS

This prospective study was conducted in compliance with the institutional and government review board regulations, informed consent regulations, and the
Declaration of Helsinki during a three-year period. Written informed consent was obtained from all patients and control subjects before the clinical and radiological evaluations.

Twenty NF-1 patients without OPG (group 1), 16 NF-1 patients with OPG (group 2), and 19 healthy subjects with normal neurological and ophthalmological examinations (control group) were enrolled in this study. Subjects with any history of neurological disease, allergy, claustrophobia, ferromagnetic implants or pacemakers, renal failure, meningitis, and pregnancy were excluded. In five cases, screening failures occurred. These cases were also excluded from the study. The presence or absence of OPG was defined subjectively by an experienced neuroradiologist (O.A.) according to the literature [1-8]. Presence of headache was also questioned and recorded, subjectively.

The diagnosis of NF-1 was made according to the National Institutes of Health Consensus Development Conference diagnostic criteria [1]. After the neuro-ophthalmological examination, 3T-MRI acquisitions were obtained from all subjects. The neuroradiologist (O.A.) evaluated the MRI data during acquisition; if needed, intravenous contrast media (0.3 ml/kg Dotarem) was administered before the 3D-SPACE and STIR sequences and post-contrast T1W images were obtained. The MRI protocol is given in Table 1. MRI examinations were performed using a 3T unit (Trio with Tim; Siemens Healthcare AG, Erlangen, Germany) with a birdcage-multichannel head coil.

Multiplanar and curved reformatted images were obtained with Neuro 3D software (Siemens Healthcare AG, Germany) except STIR sequence (because routine
STIR is a 2D sequence). The thickness of the ON and the diameter of the ONS were measured on short tau inversion recovery (STIR) and 3D-SPACE images by another neuroradiologist (M.B.). For each eye, two measurements were made from the thickest part of the ON and ONS, which did not involve the qualitatively (visually) detectable part of the OPG (Figure 1). The mean value of these two measurements was calculated and considered as the exact value of each eye. The measurements were made in a uniform manner between outer margins on axial and coronal images, subjectively by each rater. The rater (M.B.) was blinded to the patient group during the evaluations. All measurements were made for intraconal thickest part of the optic nerve for both eyes, separately. If the ON and/or ONS boundaries could not be clearly chosen due to intraconal glioma, these parameters of the eyes were not included in the statistical analyses of the study.

Optic nerve tortuosity was assessed by the neuroradiologist (M.B.) and graded as follows:

Grade 0: No tortuosity

Grade 1: Mild tortuosity

Grade 2: Moderate tortuosity

Grade 3: Severe tortuosity

The optic pathways including optic radiations were also evaluated for the presence of any NBO, hamartoma, myelin defect, axonal defect or OPG. Gliomas of the optic pathways were defined based on hyper-intense appearance (on FLAIR or T2W images) and thickening of optic pathway structures [8]. The location (pre-chiasmatic,
chiasmatic, post-chiasmatic) and the laterality (right sided, left-sided, bilateral) of the glioma in patients with OPG were classified. Findings of STIR and 3D-SPACE sequences were compared between groups and according to clinical findings.

**Statistical Analysis**

Continuous variables were reported with median, minimum-maximum values and categorical variables were presented as frequency and percentage. Kruskal Wallis and Mann Whitney-U tests were performed for groups’ comparisons. Categorical variables were compared between groups using the Pearson Chi-square test, Fisher's exact test, and the Fisher Freeman Halton test. For determining the reliability of 3D-SPACE and STIR measurements, the Intra-class Correlation Coefficient (ICC) was used. Statistical significance was set at p<0.05.

**RESULTS**

Group 1 consisted of 20 patients. There were 10 male and 10 females with a mean age of 17.8 (7-41) years. Group 2 comprised 16 patients including 7 (43.8%) male and 9 (56.2%) female. Their mean age was 12 (6-21) years. The OPGs were right sided in 4 (25%), left side in 2 (12.5%), and bilateral in 10 (62.5%) patients in group 2. The control group consisted of 19 subjects, 9 (47.4%) male and 10 (52.6%) female with a mean age of 18.3 (5-34) years.

The mean ONS diameters on STIR images were significantly higher in group 2 compared to group 1 and controls (p=0.009) (Table 2). The mean ONS diameter was significantly higher in group 2 when compared to group 1 and the control group with the 3D-SPACE sequence (p=0.017, Table 2). It was 4.4 mm (3.3-6.3), 5.4 mm (3.2-
14.5), and 5.1 mm (4.2-6.5) in group 1, group 2, and the control group, respectively (p=0.019 for groups 1 and 2, p=0.007 for group 1 and control group, p=0.607 for group 2 and control group) (Table 2).

The measurements of ONS diameter obtained from STIR and 3D-SPACE sequences were significantly correlated with each other (p<0.001, ICC: 0.88, Table 3). Comparing the distribution of the ON tortuosity grades across the controls and group 1 and group 2 (Table 4), control subjects had significantly lower grades than both groups (p=0.001). Group 1 also had significantly lower tortuosity grades when compared to group 2 (p=0.001). Severe (grade 3) tortuosity was only detected in group 2.

In group 1 and group 2, 7 (35%) and 5 (31.2%) patients had a positive family history of NF-1, respectively. Seven (35%) patients in group 1 and 3 (18.7%) patients in group 2 had Lisch nodules. There was no association between the presence of any OPG and having a positive family history, presence of any Lisch nodule or hydrocephalus (p>0.05). Patients with headaches had higher (but not significant statistically) ON thickness and ONS diameter when compared to patients without headaches (Table 5).

Partial or complete type aqueduct stenosis was detected in 6 of NF-1 patients of whom 3 had hydrocephalus (two patients in group 1 and one patient in group 2) and the other 3 had functioning ventriculoperitoneal shunt (VPS) systems (Figure 2). Cranial MRI findings (except NBOs or gliomas) of all NF-1 patients are given in Table 6. In total, 109 NBOs were detected in group 1, and 97 were detected in group 2 with the STIR sequence imaging. 3D-SPACE imaging demonstrated additional 26 NBOs in group 1 and 17 NBOs in group 2 patients.
DISCUSSION

This paper focuses on two main topics, the description of the optic nerve in patients with NF1, and the comparison of NF1 related findings on routinely performed MRI sequence (2D-STIR) versus an upcoming high-resolution 3D-MRI acquisition (3D-SPACE). Patients with OPG are at risk for vision loss. Optic pathway gliomas are one of the seven diagnostic criteria of NF-1 [1-8]. The ophthalmologic examination may show optic nerve dysfunction. Dilatation of the ONS and tortuosity of ON are other common MRI findings in NF-1 patients [12-14]. ONS dilatation is the non-progressive enlargement of the subarachnoid space surrounding the optic nerve, synonymous with dural ectasia of the ONS [15]. ONS dilatation is a sign, not a disease; and can easily be detected and measured with MRI and CT scans. It is caused by underlying processes, which themselves may need treatment, but ONS dilatation itself does not need treatment.

Recent research indicates that ONS dilatation could be a good indicator of raised intracranial pressure (ICP) in NF-1 patients (14). Therefore, ONS fenestration, a surgical procedure to reduce the pressure within the subarachnoid space of the optic nerve, could be helpful in the treatment of severe ONS dilatation associated with progressive visual loss due to the papilledema [14-16]. Optic nerve sheath dilatation can occur for other reasons unrelated to high ICP and these cases are unlikely to benefit from ONS fenestration.

Increased ON tortuosity has been demonstrated in the optic pathway of NF-1 patients in a few reports [8, 12-14]. In a recent study; the incidence of ON tortuosity was reported as 84% in NF-1 patients [17]. The two most reliable features of ON tortuosity were; lack of congruity in greater than one coronal section, and dilation of the subarachnoid space surrounding the anterior portion of the ON. Levin et al.’s study
revealed ON tortuosity on baseline MRI was a predictor of subsequent OPG in NF-1 patients, but not a predictor of clinically significant OPG requiring treatment or resulting in poor vision. ON thickness or ONS dilatation were not associated with later appearance of OPG [8].

In the present study, we evaluated the optic pathways of NF-1 patients with 3T MRI unit. We assessed and compared the thickness and the tortuosity of ON and the diameter of ONS in patients with or without OPG by 3D-SPACE and STIR sequences. Our study demonstrated that the diameter of ONS was significantly higher in NF-1 patients regardless of the presence of OPG. The ON thickness did not show any significant difference between NF-1 patients and healthy subjects. We think that this result is related to our measurement location. Because, we measured the ON diameter apart from the visible OPG in NF1 patients with OPG. The aim of this manner was to evaluate the normal appearing parts of the ONs.

The relationship between raised intracranial pressure and the dilatation of the ONS has been known for several years [15-18]. Also, it is known that NF-1 is associated with altered or worsened CSF circulation due to fibrotic changes of the arachnoid membranes [19]. Mild or moderate intracranial hypertension might be present in NF-1 patients regardless of having any OPG. Supporting this hypothesis, we observed headache was more common in NF-1 patients with more dilated ONS. According to our data, ONS diameter will not relate solely or principally to the presence or absence of an OPG. In many cases, the ONS dilates secondary to the intracranial phenomena. We believe that studies monitoring the pressure of cerebrospinal fluid are needed to support our findings.
ON tortuosity was assessed subjectively in our study. Our findings revealed that the average ON tortuosity for NF-1 patients with OPG was higher than the NF-1 patients without OPG. NF-1 patients without OPG also had more tortuous ONs when compared to healthy subjects. Grade 3 ON tortuosity was only detected in NF-1 patients with OPG, while healthy subjects had none. We think that increased ON tortuosity in NF-1 patients may also indicate raised intracranial pressure and support our previous findings.

Additionally, our results indicated that 3D-SPACE and STIR sequences both provide valuable imaging information on the diameter of ONS. Thin-section conventional sequences would be preferable in evaluating the morphology of the ON or other cranial structures of the NF-1 patients [9]. Isotropic 3D-SPACE (<1 mm³) data is useful for evaluation of these details and has a complementary capability for multiplanar high-resolution CSF and the whole cranial evaluation, but it needs more experience. Importantly, 3D-SPACE and conventional sequences for assessment of optic pathway structures seem to complement each other and give partly different information. 3D-SPACE imaging provides useful imaging information to be of potential use in daily clinical practice in easy screening the optic pathway and the whole cranium with high resolution and low SAR levels [11].

Relationship between CSF related disorders (especially hydrocephalus) and NF-1 has already been reported [9-19]. In our study, 3D-SPACE sequence was adequate for imaging of our patients with hydrocephalus or ventriculoperitoneal shunt, and their other intracranial findings. In the literature, 3D-SPACE technique was reported as the most adequate, easy and fast sequence to determine the ventricular system and CSF related pathologies [20-21].
There are many T2W 3D-SPACE or 3D-TSE sequences for evaluation of the cranium or brain [20]. 3D-SPACE sequence of this study is not a heavily T2-weighted sequence. It is a 3D-turbo spin echo (3D-TSE) sequence with variant FA values [21]. According to our observations, the increased signal intensity of some lesions (e.g. it is an important feature of optic nerve gliomas) may not be evaluated perfectly on 3D-SPACE images. As a radiologist perspective; in the absence of other findings, the tortuosity of the ON may cause confusion among the clinicians about the presence of optic nerve glioma in the patient. The point is that the ON tortuosity is not a unique indicator about the presence of optic pathway gliomas.

According to the literature, upper limit or threshold value for ONS diameter is 6 mm in healthy children or adolescents [22]. Our findings are consistent with these statements. Median ONS values of our control group for 3D-SPACE and STIR sequences are 5.1 and 5.7 mm, respectively.

In contrast with the ONS diameter, the ON measurements were not correlated between the 3D-SPACE and STIR sequences (Table 3). These results are probably since 3D-SPACE with variant or variable FA technique is more sensitive to the delineation of intraconal ON than the STIR images. On this type 3D-SPACE images, intraconal ON visibility is lesser than the STIR images. Because, STIR is a fluid sensitive, fat-saturated, and relatively heavily T2W technique. 3D-SPACE or 3D-TSE images with constant FA values may be more useful for delineation ON/ONS and comparison of these values with STIR sequence.

There are some limitations to our study. First, the monitoring with MRI and clinical exam frequently decreases dramatically after age 8. Furthermore, OPGs are
known to regress into adulthood. Since sedation was needed, we could not include more pediatric cases in the study groups. **Second**, the proof or exclusion of an OPG was subjectively determined due to ethical reasons. Enlargement of the optic nerve in the setting of NF1 is assumed to be OPG and biopsy confirmation is not generally required. Contrast-material enhancement on T1W images suggests more active disease, but OPG is suspected even in non-enhancing slight expansion of the optic nerve. However, the exact diagnosis of the OPG is made by biopsy. **Third**, the cross-section of the optic nerve is around 3 mm in all three groups. The voxel sizes of 3D-SPACE and 2D-STIR sequences are 0.6×0.6×0.6 and 0.6x0.5x3 mm, respectively. These values may be inadequate for optic nerves, and subtle size differences are within the margin of error (especially for STIR images). **Fourth**, this is a small study in which statistically STIR performed slightly better than 3D SPACE imaging in assessing ON thickness. Also, STIR can offer an advantage in terms of assessment of optic nerve signal. **Finally**, inter-rater and intra-rater variability assessments would be helpful for optimal detection of possible differences between sequences and other parameters.

**In conclusion**, our findings revealed that ON is more tortuous and ONS is more dilated in NF-1 patients (especially cases with OPG). Additionally, high-resolution 3D cranium imaging with 3D-SPACE is useful for the management of patients with NF-1. The 3D-SPACE technique is safe, efficient, and relatively easy in assessing the optic pathways in NF-1 patients. In the current study, we apparently demonstrated the equivalency of T2W 3D-SPACE versus STIR for measurement of the ON and ONS in the NF1 population and controls. Further studies with large patient groups are needed to support our findings.

**Declaration of interest:** The authors report no conflicts of interest.
References


22- Janthanimi P, Dumrongpisutikul N. Pediatric optic nerve and optic nerve sheath diameter on magnetic resonance imaging. Pediatric Radiology 2019; 49: 1071–1077

FIGURE LEGENDS
**Figure 1:** Optic nerve (ON) and optic nerve sheath (ONS) measurements (arrows) of 3 patients with NF-1 on STIR (left and middle) and 3D-SPACE (right) images.

**Figure 2:** 3D-SPACE (T2W with variant FA mode) (A, B) and contrast-material enhanced MPRAGE (C-F) images of an NF-1 patient with optic pathway glioma (arrows) and aqueduct stenosis due to tectal glioma (dashed arrow).

**TABLES**

**Table 1:** 3 Tesla MRI protocol used for the study.

<table>
<thead>
<tr>
<th>Sequences/Parameters</th>
<th>3D-MPRAGE</th>
<th>3D-SPACE (with VFAM)</th>
<th>STIR</th>
<th>FLAIR</th>
</tr>
</thead>
<tbody>
<tr>
<td>TR/TE (ms)</td>
<td>2130/3.45</td>
<td>3000/579</td>
<td>5100/81</td>
<td>6000/405</td>
</tr>
<tr>
<td>TI (ms)</td>
<td>1100</td>
<td>-</td>
<td>150</td>
<td>2100</td>
</tr>
<tr>
<td>Slice thickness (mm)</td>
<td>0.8</td>
<td>0.6</td>
<td>3</td>
<td>0.9</td>
</tr>
<tr>
<td>FOV* (mm)</td>
<td>230x230</td>
<td>240x240</td>
<td>230x230</td>
<td>230x230</td>
</tr>
<tr>
<td>Acquisition time (minute)</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>NEX</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Number of slices</td>
<td>240</td>
<td>240</td>
<td>16</td>
<td>192</td>
</tr>
<tr>
<td>Flip angle (°)</td>
<td>8</td>
<td>100</td>
<td>120</td>
<td>-</td>
</tr>
<tr>
<td>Imaging plane</td>
<td>Sagittal</td>
<td>Sagittal</td>
<td>Axial-coronal</td>
<td>Sagittal</td>
</tr>
<tr>
<td>Distance factor</td>
<td>-</td>
<td>-</td>
<td>10%</td>
<td>-</td>
</tr>
<tr>
<td>PAT factor</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>--</td>
</tr>
<tr>
<td>PAT mode</td>
<td>GRAPPA</td>
<td>GRAPPA</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Voxel size (mm)</td>
<td>0.8x0.8x0.8</td>
<td>0.6x0.6x0.6</td>
<td>0.6x0.5x3</td>
<td>0.9x0.9x0.9</td>
</tr>
<tr>
<td>FA mode</td>
<td>-</td>
<td>T2 variant</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Notes = TI: time of inversion; 3D-SPACE: three-dimensional sampling perfection with application-optimized contrasts using different flip angle evolutions; 3D-MPRAGE: 3D T1W magnetization prepared rapid acquisition gradient-echo; STIR: short tau inversion-recovery; FLAIR: fluid-attenuated inversion-recovery; NEX: number of excitations; FOV: field of view; PAT: parallel acquisition technique; GRAPPA: generalized auto calibrating partially parallel acquisitions. The advantage of 3D acquisition is the capability to reconstruct the images at any angle and align with other acquisitions. Thus, multiplanar images were obtained from 3D MPRAGE, SPACE and FLAIR acquisitions.

Table 2: The median thickness of the optic nerve (ON) and the diameter of the optic nerve sheath (ONS) measured with two different MRI sequences in groups.

<table>
<thead>
<tr>
<th>MRI Sequence</th>
<th>Group 1 Median (min-max)</th>
<th>Group 2 Median (min-max)</th>
<th>Controls Median (min-max)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>ONS-SPACE (mm)</td>
<td>4.4 (3.3-6.3)</td>
<td>5.4 (3.2-14.5)</td>
<td>5.1 (4.2-6.5)</td>
<td>0.017</td>
</tr>
<tr>
<td>ON-SPACE (mm)</td>
<td>2.3 (1.5-3.5)</td>
<td>2.5 (1.4-34)</td>
<td>2.4 (1.7-3.7)</td>
<td>0.193</td>
</tr>
<tr>
<td>ONS-STIR (mm)</td>
<td>5.3 (4.3-7.3)</td>
<td>6.7 (4.4-14)</td>
<td>5.7 (5-7.3)</td>
<td>0.009</td>
</tr>
<tr>
<td>ON-STIR (mm)</td>
<td>3.2 (2.3-4.4)</td>
<td>3 (1.7-10)</td>
<td>2.8 (2.1-3.8)</td>
<td>0.804</td>
</tr>
</tbody>
</table>

Group 1: NF-1 patients without optic pathway glioma (OPG)
Group 2: NF-1 patients with OPG

Table 3: The compatibility and the correlation analyses of the two methods (3D-SPACE and STIR) for the thickness of the optic nerve (ON) and the diameter of the optic nerve sheath (ONS).
Table 4: The grades of optic nerve tortuosity in groups.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Controls</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td># (%)</td>
<td># (%)</td>
<td># (%)</td>
<td># (%)</td>
</tr>
<tr>
<td>0</td>
<td>6 (30)</td>
<td>2 (7.7)</td>
<td>17 (89.5)</td>
<td>25 (38.5)</td>
</tr>
<tr>
<td>1</td>
<td>9 (45)</td>
<td>9 (34.6)</td>
<td>2 (10.5)</td>
<td>20 (30.8)</td>
</tr>
<tr>
<td>2</td>
<td>5 (25)</td>
<td>4 (15.4)</td>
<td>0 (0)</td>
<td>9 (13.8)</td>
</tr>
<tr>
<td>3</td>
<td>0 (0)</td>
<td>11 (42.3)</td>
<td>0 (0)</td>
<td>11 (16.9)</td>
</tr>
</tbody>
</table>

Group 1: NF-1 patients without optic pathway glioma (OPG)

Group 2: NF-1 patients with OPG

Table 5: Relationship between the thickness of the optic nerve (ON) and optic nerve sheath (ONS) diameter with the presence of headache in all NF-1 patient cohort.
<table>
<thead>
<tr>
<th>Sequence</th>
<th>ON/ONS</th>
<th>No Headache</th>
<th>Headache</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median (min-max)</td>
<td>Median (min-max)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STIR</td>
<td>ON</td>
<td>2.90 (1.70-4.20)</td>
<td>3.35 (2.50-5.30)</td>
<td>0.182</td>
</tr>
<tr>
<td></td>
<td>ONS</td>
<td>5.70 (4.30-8.40)</td>
<td>6.10 (4.80-8.50)</td>
<td>0.457</td>
</tr>
<tr>
<td>3D-SPACE</td>
<td>ON</td>
<td>2.40 (1.50-34)</td>
<td>2.40 (1.80-4.90)</td>
<td>0.585</td>
</tr>
<tr>
<td></td>
<td>ONS</td>
<td>5 (3.20-6.50)</td>
<td>5.10 (3.50-8)</td>
<td>0.499</td>
</tr>
</tbody>
</table>

Table 6: Cranial MRI findings (except UBOs) of NF-1 patients in groups 1 and 2.
<table>
<thead>
<tr>
<th>Group 1</th>
<th>Number of patients</th>
<th>Number of pathologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperintense bone lesion on T2W images</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Mucosal thickening of the paranasal sinuses</td>
<td>5</td>
<td>13</td>
</tr>
<tr>
<td>Cavum septum pellucidum</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>An abnormal course of the optic nerve</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Adenoid vegetation</td>
<td>4</td>
<td>4 (bilaterally)</td>
</tr>
<tr>
<td>Pineal cyst</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Encephalomalacia due to trauma or surgery</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Intracranial cystic lesion (e.g. arachnoid cyst)</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Intracranial hypotension</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group 2</th>
<th>Number of patients</th>
<th>Number of pathologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-optic pathway glioma</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Mucosal thickening of the paranasal sinuses</td>
<td>7</td>
<td>16</td>
</tr>
<tr>
<td>Adenoid vegetation</td>
<td>4</td>
<td>4 (bilaterally)</td>
</tr>
<tr>
<td>Encephalomalacia due to trauma or surgery</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Contrast-material enhanced glioma</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Hyperintense bone lesion on T2W images</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Hypophyseal adenoma</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Mega cisterna magna</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

*Note* = Group1: NF-1 patients without optic pathway glioma (OPG), Group 2: NF-1 patients with OPG